Filing Details

Accession Number:
0001209191-11-051706
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-10-13 17:18:57
Reporting Period:
2011-10-11
Filing Date:
2011-10-13
Accepted Time:
2011-10-13 17:18:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1135906 Zalicus Inc. ZLCS Pharmaceutical Preparations (2834) 043514457
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1173408 L.p. Iii Bioventures Mpm C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1173409 L.p. Iii-Qp Bioventures Mpm C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1249063 Mpm Bioventures Iii Parallel Fund, L.p. C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1249133 Mpm Bioventures Iii Gmbh & Co. Beteiligungs Kg C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1249141 Mpm Asset Management Investors 2003 Bviii Llc C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1249143 L.p. Gp Iii Bioventures Mpm C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1249147 Mpm Bioventures Iii Llc C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1263048 Mpm Asset Management Llc C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-10-11 206,500 $1.02 13,132,029 No 4 S Indirect See Footnote
Common Stock Disposition 2011-10-12 131,800 $102.00 13,000,229 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. The shares were sold as follows: 170,998 by MPM BioVentures III-QP, L.P. ("BV III QP"), 11,498 by MPM BioVentures III, L.P. ("BV III"), 3,331 by MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), 5,164 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel"), 14,452 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG") and 1,077 by MPM Asset Management LLC ("MPM AM").
  2. Represents weighted average sales price. The shares were sold at prices ranging from $1.02 to $1.03. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. The shares are held as follows: 10,877,040 by BV III QP, 730,177 by BV III, 210,294 by AM 2003, 327,504 by BV Parallel, 917,999 by BV KG and 69,015 by MPM AM. MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2003. Luke Evnin and Ansbert Gadicke are members of MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
  4. The shares were sold as follows: 109,142 by BV III QP, 7,338 by BV III, 2,113 by AM 2003, 3,296 by BV Parallel, 9,224 by BV KG and 687 by MPM AM.
  5. The shares are held as follows: 10,767,898 by BV III QP, 722,839 by BV III, 208,181 by AM 2003, 324,208 by BV Parallel, 908,775 by BV KG and 68,328 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.